Back to search results

Study of AG1 Supplement for GLP-1 RA Users

This study is looking at how a nutritional supplement called AG1 affects people who are taking GLP-1 receptor agonists (GLP-1 RAs) like Ozempic®, Wegovy®, or Trulicity®. Researchers want to see if AG1 can help fill nutrient gaps and improve gut health. You might be able to join if you are between 18 and 59 years old, have a BMI between 20-31.9, and are currently taking a GLP-1 RA at a steady dose. The main goal is to measure nutrient gaps after 90 days to see if the supplement makes a difference. This study is triple-blind, meaning you, your doctor, and the researchers won't know if you're getting AG1 or a placebo (an inactive substance like maltodextrin).

Study design
This is a randomized, triple-blind, placebo-controlled study involving 120 adults. Participants will be randomly assigned to receive either the AG1 supplement or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, nutrient gaps, is measured at 90 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07437911

A Randomized, Triple-blind, Placebo-controlled Study to Evaluate the Effects of a Supplement on Nutrient Gaps and Gut Health Among Individuals Utilizing GLP-1 RAs

Recruiting
NAAges 18–59InterventionalSupportive care
Athletic Greens International
~120 participants
Updated 2026-02-27 on ClinicalTrials.gov
What's tested:AG1 - Nutritional SupplementPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Nutrient Gaps
Measured over 90 days

Conditions

Nutrition Intake
Nutrition Status
Gastrointestinal Microbiome
GLP-1

Explore related trials

Nutritional Deficiency

Where it's being run

1 sites across 1 states
California1

Who to contact

Ellen O'Gorman
[email protected]
(805) 292-0714
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be male or female
Be aged 18-59.
Has a BMI between 20-31.9.
Anyone currently taking GLP-1 medication at their maintenance dose (week 8+), and without any plans to alter their dosage. This includes: Semaglutide (Ozempic®, Wegovy®, Rybelsus®), Liraglutide (Saxenda®, Victoza®), Dulaglutide (Trulicity®), Exenatide (Byetta®, Bydureon®), Lixisenatide (Adlyxin®)
Anyone willing to follow the study protocol, including immediately prior to the all blood tests, duplicating their diet for 72 hours (3 days), refraining from caffeine and exercise for 24 hours, and fasting for 10 hours.
Anyone willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial.
Anyone willing to avoid introducing any other supplements, medications, or herbal remedies for the duration of this trial.
Anyone who is generally healthy - does not live with any diagnosed uncontrolled chronic disease.
Has access to a consistent weighing scale for the duration of the study.
Resides in the United States.

Exclusion

Anyone with a diagnosis of Type I or Type II diabetes.
Anyone with a diagnosis of any metabolic health condition, such as hypertension and dyslipidemia.
Anyone who has taken any multivitamin/multimineral supplements within the past 3 months.
Anyone who has taken a probiotic supplement within the past month.
Anyone who has regularly consumed (5 days/week or more) products that target healthy aging, anti-aging, longevity, gut health, energy, or ingestive behaviour (such as cravings), including resveratrol, quercetin, pterostilbene, coQ10, grapefruit, nicotinamide riboside, prebiotic fiber, green tea, niacin (vitamin B3) within the past 2 months.
Anyone who has received an antibiotic, antifungal, antiparasitic, or antiviral treatment within the past 90 days.
Anyone who has a known history of severe digestive disorders or metabolic conditions that impact nutrient absorption or metabolism, including acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, a history of colon resection, gastroparesis, Inborn errors of metabolism (such as PKU), or gastrointestinal tract surgeries.
Anyone with any known allergies or hypersensitivities to any supplement product ingredients.
Anyone with any chronic health conditions that could impact participation in this study, such as asthma, gout, fibromyalgia, chronic inflammatory conditions (such as Crohn's, Lupus, HIV/AIDS), thyroid conditions, cancer (within the past 5 years), mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period.
Anyone currently pregnant, trying to conceive, or breastfeeding.
Anyone who has undergone a change in hormone therapy (including oral contraceptives) within the past 4 weeks, or is unwilling to maintain their current hormone therapy/oral contraceptive use throughout the course of the study.
Anyone who consumes more than 2 standard alcoholic drinks per day or more than 10 drinks per week, or has within the past 6 months.
Anyone who is currently a smoker or has been a smoker within the past month.
Anyone who follows a specific exclusion diet, including vegan, vegetarian, carnivore, paleo, atkins, or ketogenic.

What this trial measures

  • Nutrient Gaps90 days

    Assess nutrient gaps by dietary record assessment utilizing The Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool